LA
STLN

Linden Advisors’s Starling Oncology STLN Stock Holding History

Linden Advisors’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-97,271
Closed -$970K – 842
2021
Q1 		$970K Sell
97,271
-2,729
-3% -$29.1K 0.01% 517
2020
Q4 		$1.08M Hold
100,000
– – 0.01% 373
2020
Q3 		$1.04M Hold
100,000
– – 0.01% 252
2020
Q2 		$1M Buy
+100,000
New +$995K 0.02% 188

Other funds holding STLN

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.47B AUM 86.42% 1-Year Est. Return
KLC
Kent Lake Capital Reno, Nevada $222M AUM 18.04% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return
TAL
TIG Advisors LLC New York $2.26B AUM 81.38% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Linden Advisors's STLN Position: Q2 2021 in Review

Linden Advisors sold out of Starling Oncology (STLN) in Q2 2021, closing a stake of 97,271 shares — an estimated $970K sold.

Linden Advisors first reported a position in STLN in Q2 2020 and held it in 4 quarters. The position peaked at $1.08M in Q4 2020. 53 funds tracked by Wall St. Rank hold STLN as of Q2 2021.

  • Linden Advisors reported no remaining Starling Oncology position as of Q2 2021 after selling out during the quarter.
  • Linden Advisors sold 97,271 Starling Oncology shares in Q2 2021, an estimated $970K.
  • Linden Advisors first reported a position in Starling Oncology in Q2 2020 and held it in 4 quarters.
  • Linden Advisors's Starling Oncology position peaked at $1.08M in Q4 2020.
  • 53 funds tracked by Wall St. Rank held Starling Oncology as of Q2 2021.

Based on Linden Advisors's 13F filing for Q2 2021, filed 16 Aug 2021.